Previous Close | 5.35 |
1-Year Change | 71.47% |
6-Months Change | 55.52% |
3-Months Change | -0.93% |
Moving Avg (50d) | 5.0186 |
Moving Avg (200d) | 4.6874 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 316.7M |
Beta (3-Years) | 1.39 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | % |
Return On Assets (ttm) | -31.02% |
EPS (ttm) | -0.24 |
PE Ratio (ttm) | -22.29 |
Dividend Yield | % |
Asset Description: | Aldeyra Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-15 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
5.243 | 5.082 | 4.975 | 4.815 | 4.547 | 4.28 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.